



NEWS RELEASE

ChromaDex and Watsons Launch New TRU NIAGEN® EX Stick Packs in Hong Kong, Expanding Product Line and Advancing Global Retail Partnership

11/9/2020

ChromaDex and Watsons Hong Kong launch new TRU NIAGEN® EX stick packs for on-the-go consumers in new delivery method

LOS ANGELES--(BUSINESS WIRE)-- ChromaDex Corp. (NASDAQ:CDXC) announced today the exclusive launch of its TRU NIAGEN® EX Stick Packs with Watsons Hong Kong, available online and in all Watsons Hong Kong stores. TRU NIAGEN® has been the #1 selling supplement in Watsons Hong Kong, and TRU NIAGEN® EX offers an alternative delivery method for the well-studied healthy aging vitamin, available to mix with one's favorite beverage or sports drink.

This press release features multimedia. View the full release here:

<https://www.businesswire.com/news/home/20201109005305/en/>

TRU NIAGEN® EX launches in Watsons Hong Kong (Graphic: Business Wire)

"The health-oriented customers at Watsons have made TRU

NIAGEN® a best-selling product in Hong Kong," says ChromaDex CEO Rob Fried. "TRU NIAGEN® EX will help us reach the active, fitness-oriented consumer who drinks sports beverages and protein shakes."

ChromaDex and A.S. Watson Group have been in partnership since 2017 with product launches in Hong Kong, Singapore, and the United Kingdom. TRU NIAGEN® has received several awards as a favorite product amongst Watsons loyalty members. TRU NIAGEN® EX stick packs further broaden the spectrum of potential consumers.

The stick packs, which each provide 300mg nicotinamide riboside mixed with fiber source inulin (chicory root extract), will offer consumers single-serving packets that easily mix into both cold and warm beverages, including smoothies and coffee. The vegetarian and caffeine-free product is suitable for people who are looking for an extra NAD+ boost for cellular energy and repair.

“Our customers have demonstrated a steadfast commitment to improving their health every day, and we constantly look for ways to provide innovative and user-friendly solutions to help,” says Samuel Lee, Managing Director of Watsons Hong Kong. “As one of our top selling health products, TRU NIAGEN® has been a widely sought after supplement. We are confident that our customers will be thrilled with the expansion of our partnership with ChromaDex as it provides them with a new option that can be easily implemented into any health routine.”

Supporting cellular defense and repair by boosting NAD+ levels is important for healthy aging. NAD+ levels decline with age as well as physiological stressors including stress on the immune system, alcohol consumption, over-exercising, and lack of healthy sleep cycles. NIAGEN® increases NAD+ levels safely and efficaciously, as demonstrated in nine published human trials.

For additional information on the science supporting TRU NIAGEN®, please visit www.truniagen.com.

For additional information on Watsons, please visit www.watsons.com.hk.

About ChromaDex:

ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of NAD and its impact on human health. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to whether TRU NIAGEN® EX will help the Company reach the active, fitness-oriented consumer. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential,"

"possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 as amended, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20201109005305/en/>

ChromaDex Media Contact:

Alex Worsham, Vice President of Global Marketing & Communications

310-388-6706 ext. 689

alexw@chromadex.com

ChromaDex Investor Relations Contact:

Brianna Gerber, Vice President of FP&A and Investor Relations

949-419-0288 ext. 127

briannag@chromadex.com

Source: ChromaDex Corporation